hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06329297, orgStudyIdInfo id: NUR23-1005 INPTCGM1, briefTitle: Continuous Glucose Monitoring in Inpatients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Parkview Health, class: OTHER, descriptionModule briefSummary: The purpose of this study is to contribute to current research regarding the feasibility and accuracy of CGM in the hospital setting for both the medical and cardiovascular intensive care (ICU) patient populations., conditionsModule conditions: Hyperglycemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: CGM monitor, outcomesModule primaryOutcomes measure: CGM vs point of care test (POCT) glucose, secondaryOutcomes measure: Slow downward trend arrow on CGM device, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329284, orgStudyIdInfo id: RC 31.1.2024, briefTitle: Midkine Role With Deregulated Oxidative and Immune Milieu in Induction of Preeclampsia, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-09-15, completionDateStruct date: 2023-12-15, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Benha University, class: OTHER, descriptionModule briefSummary: Preeclampsia (PE) is a hypertensive pregnancy-related disorder that endangers maternal and fetal outcomes and accounts for 9-10% of maternal mortalities with its early-onset phenotype is the most dangerous, but its etiology is still not fully elucidated.Midkine (MDK) is a multifunctional protein that plays a unique role in the development of hypertension (HTN), via its proatherogenic effect and induction of overexpression of angiotensin converting enzyme. Oxidative stress (OS) upregulates the expression of MDK and MDK induces propagation of neoangiogenesis and acts as chemotactic for neutrophils., conditionsModule conditions: Pre-Eclampsia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Newly pregnant normotensive (NT) women with singleton fetus, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ACTUAL, armsInterventionsModule interventions name: ELISA, outcomesModule primaryOutcomes measure: Severity of Pre-Eclampsia (PE), eligibilityModule sex: FEMALE, minimumAge: 21 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Banha University, city: Banhā, state: El- Qalyobia, zip: 13511, country: Egypt, geoPoint lat: 30.45906, lon: 31.17858, hasResults: False
protocolSection identificationModule nctId: NCT06329271, orgStudyIdInfo id: 113022-E, briefTitle: After Hip Fracture Nailing, Compare Early Weight Bearing as Tolerated (WBAT) Group With Weight Bearing Restriction(WBR), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2025-04-29, completionDateStruct date: 2025-04-29, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Far Eastern Memorial Hospital, class: OTHER, descriptionModule briefSummary: Purpose: Proximal femur fracture is a major traumatic injury in elderly populations; however, practical postoperative weight-bearing protocols are lacking. Therefore, the purpose of the present study was to investigate whether early weight-bearing status after proximal femur nail fixation is associated with any loss of reduction and evaluate the clinical outcomes of this intervention.Patients and methods:For this prospective single-center clinical trial study, we recruited 60 geriatric proximal femur fracture cases, classified by AO/OTA 2018, receiving intramedullary nail fixation. The participants were assigned to the Early-weight-bearing group (n= 30) or the Weight-bearing restriction group (n = 30). Clinical outcomes included the Harris functional hip score and VAS pain score. Additionally, demographic data, radiological parameters, time to weight-bearing, mortality rate, medical and surgical complications, and final ambulation status were recorded., conditionsModule conditions: Bony Weight Bearing Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Early-Weight bearing, outcomesModule primaryOutcomes measure: Harris Hip Functional score, primaryOutcomes measure: Harris Hip Functional score, primaryOutcomes measure: Harris Hip Functional score, primaryOutcomes measure: Harris Hip Functional score, primaryOutcomes measure: Harris Hip Functional score, secondaryOutcomes measure: Visual analog pain score, secondaryOutcomes measure: Visual analog pain score, secondaryOutcomes measure: Visual analog pain score, secondaryOutcomes measure: Visual analog pain score, secondaryOutcomes measure: Visual analog pain score, secondaryOutcomes measure: Complication, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Far-Eastern Memorial Hospital, status: RECRUITING, city: New Taipei City, zip: 220, country: Taiwan, contacts name: Yen Cheng Chen, role: CONTACT, phone: 886919207805, email: sstteevveepp@gmail.com, geoPoint lat: 25.01111, lon: 121.44583, hasResults: False
protocolSection identificationModule nctId: NCT06329258, orgStudyIdInfo id: PTC09, briefTitle: Combination of Sotyktu and Enstilar for Plaque Psoriasis, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-06, primaryCompletionDateStruct date: 2023-11-13, completionDateStruct date: 2023-11-13, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Psoriasis Treatment Center of Central New Jersey, class: OTHER, descriptionModule briefSummary: combination deucravacitinib and enstilar foam, conditionsModule conditions: Psoriasis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: open label, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Enstilar, interventions name: Deucravacitinib, outcomesModule primaryOutcomes measure: Psoriasis Area and Severity Index 75 at week 12, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Schweiger Derm Group, city: East Windsor, state: New Jersey, zip: 08520, country: United States, geoPoint lat: 40.268, lon: -74.54043, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2021-08-30, uploadDate: 2024-03-14T10:41, filename: Prot_SAP_000.pdf, size: 834542, hasResults: False
protocolSection identificationModule nctId: NCT06329245, orgStudyIdInfo id: brainpro2022, briefTitle: Development of Prosocial Behaviors and Related Brain Network in Infants of High and Low Risk of ASD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2029-01-01, completionDateStruct date: 2029-07-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Children's Hospital of Fudan University, class: OTHER, collaborators name: ShanghaiTech University, descriptionModule briefSummary: The goal of this observational study is to compare the developmental trajectories of prosocial behaviors and functional network connections in infants and toddlers at high and low risk of autism spectrum disorder (ASD). The main questions it aims to answer are what the differences in prosocial behaviors and related brain network connections between infants/toddlers at high and low risk of ASD are. Participants will receive developmental and social communicational assessments (Griffiths Mental Developmental Scales, Peabody Developmental Motor Scales, The Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist), resting-state EEG and MRI in a natural sleeping state., conditionsModule conditions: Autism or Autistic Traits, conditions: Healthy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Do not take any interventions, outcomesModule primaryOutcomes measure: clinical diagnosis, primaryOutcomes measure: neurodevelopmental outcome, primaryOutcomes measure: Prosocial behaviors, primaryOutcomes measure: nuclear magnetic resonance imaging(MRI), primaryOutcomes measure: Event related potentials (ERPs), eligibilityModule sex: ALL, minimumAge: 0 Months, maximumAge: 18 Months, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329219, orgStudyIdInfo id: wIRA, briefTitle: Water-filtered Infrared-A Radiation in Patients With Hand Osteoarthritis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Charite University, Berlin, Germany, class: OTHER, descriptionModule briefSummary: The aim of this clinical trial is to evaluate the effects of water-filtered Infrared-A radiation on patients suffering from hand osteoarthritis. The main questions it aims to answer are:* Does water-filtered Infrared-A radiation reduce pain and improve the function of finger joints over time?* Are patients satisfied with the treatment results when compared to those who were on a wait-list?, conditionsModule conditions: Hand Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: water-filtered Infrared-A radiation, outcomesModule primaryOutcomes measure: Pain in the finger joints on visual analogue scale, secondaryOutcomes measure: Hand Dynamometer, secondaryOutcomes measure: Disabilities of Arm, Shoulder and Hand (DASH) questionnaire, secondaryOutcomes measure: Pain Self-Efficacy Questionnaire, secondaryOutcomes measure: Hospital Anxiety and Depression Scale (HADS), secondaryOutcomes measure: Short Form (SF)-36 Health Survey (SF-36), secondaryOutcomes measure: Functional Index for Hand OsteoArthritis (FIHOA), secondaryOutcomes measure: Tolerability of the intervention, secondaryOutcomes measure: Pain medication (number per day), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Charité - Universitätsmedizin Berlin at the Department of Internal and Integrative Medicine, Immanuel Krankenhaus Berlin, status: RECRUITING, city: Berlin-Wannsee, state: Berlin, zip: 14109, country: Germany, contacts name: Miriam Rösner, role: CONTACT, phone: +49 30 80505 682, email: naturheilkunde.studien@immanuel.de, geoPoint lat: 52.41915, lon: 13.15531, hasResults: False
protocolSection identificationModule nctId: NCT06329206, orgStudyIdInfo id: GH2616-101, briefTitle: A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2026-04-25, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Suzhou Genhouse Bio Co., Ltd., class: OTHER, collaborators name: Zhejiang Cancer Hospital, collaborators name: Henan Cancer Hospital, collaborators name: Hubei Cancer Hospital, collaborators name: The First Affiliated Hospital of Zhengzhou University, descriptionModule briefSummary: This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)., conditionsModule conditions: Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: GH2616 Tablets, outcomesModule primaryOutcomes measure: Safety assessment, secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Plasma concentration (Cmax), secondaryOutcomes measure: Area under the plasma concentration-time curve (AUC), secondaryOutcomes measure: Time to achieve Cmax (Tmax), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhejiang Cancer Hospital, status: RECRUITING, city: Zhejiang, country: China, contacts name: ZHENGBO SONG, DOCTORATE, role: CONTACT, phone: +8613857153345, email: zjccgcp_phase1@126.com, hasResults: False
protocolSection identificationModule nctId: NCT06329193, orgStudyIdInfo id: CBU-FTR-ES-O4, briefTitle: Effects of Mid-Season Camp Period Loading on Sports Injury Anxiety and Physical Performance, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-05-07, completionDateStruct date: 2024-05-15, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Celal Bayar University, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate the effects of 3-week mid-season camp period loading on sports injury anxiety level and physical performances of professional male soccer players., conditionsModule conditions: Anxiety, conditions: Exercise, conditions: Athletic Performance, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: Mid-Season Camp Period Loading, outcomesModule primaryOutcomes measure: Sports Injury Anxiety, secondaryOutcomes measure: Muscle strength, secondaryOutcomes measure: Flexibility, secondaryOutcomes measure: Dynamic balance, secondaryOutcomes measure: Single-leg jump, secondaryOutcomes measure: Agility, secondaryOutcomes measure: Sprint, eligibilityModule sex: MALE, minimumAge: 19 Years, maximumAge: 22 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06329180, orgStudyIdInfo id: 26.02.2024, briefTitle: Exercise in Mental Illness Questionnaire: French Validation, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: KU Leuven, class: OTHER, descriptionModule briefSummary: The validation of the French version of the Exercise in Mental Illness Questionnaire - Health Practitioner Version (EMIQ-HP) is a prospective observational case-only study involving: (a) translation to French, (b) an expert consensus meeting with French speaking experts from Canada to reach a first version, (c) back translation to English, (d) evaluation of the back-translation by the original authors of the EMIQ-HP, (e) an expert consensus meeting with French speaking experts from Canada to reach a final version based on comments of the original authors, and (f) test-retest reliability study. Test-retest reliability will be analysed through two points of measurement with an interval of 7 days., conditionsModule conditions: Exercise, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 42, type: ESTIMATED, outcomesModule primaryOutcomes measure: Intra-class-correlation coefficients (ICC 3,1, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre Hospitalier Psychiatrique Chêne aux Haies, city: Mons, country: Belgium, geoPoint lat: 50.45413, lon: 3.95229, hasResults: False
protocolSection identificationModule nctId: NCT06329167, orgStudyIdInfo id: 2024-HS-012, briefTitle: Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: The First Hospital of Jilin University, class: OTHER, descriptionModule briefSummary: This clinical trial is designed to learn more about treating patients with lower limb lymphoedema following gynaecological surgery. The main question to be answered is To evaluate the efficacy of Daphnetin capsule in the treatment of patients with lower limb lymphedema following gynaecological malignancy surgery. Participants will take Daphnetin capsule 150mg tid (3 capsules/time, 3 times daily) orally at the same time as gradient compression stocking treatment. Researchers will compare 150mg Forte tablets (2 capsules/time, 2 times daily) and gradient compression stockings to see if Daphnetin capsule can be used to treat patients with lower extremity lymphedema following gynaecological malignancy surgery., conditionsModule conditions: Lower Extremity Lymphedema, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Daphnetin, interventions name: Aescuven, outcomesModule primaryOutcomes measure: The difference in the circumference of the lower limbs, primaryOutcomes measure: Gynaecological Cancer Lymphedema Questionnaire, primaryOutcomes measure: Fibrinogen content, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the 1st hospital of Jilin University, status: RECRUITING, city: Chang Chun, state: Jilin, country: China, contacts name: Xiaosen Li Li, role: CONTACT, phone: +8618343116682, email: xiaosensen@jlu.edu.cn, geoPoint lat: 42.74694, lon: 126.24667, hasResults: False
protocolSection identificationModule nctId: NCT06329141, orgStudyIdInfo id: HSG4112-P2-03, briefTitle: A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Glaceum, class: INDUSTRY, descriptionModule briefSummary: 1. Study Objective   - To assess the efficacy and safety of vutiglabridin in early Parkindson's disease patients2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in early Parkinson's disease patients.3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups - 1 group receiving a placebo - in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 24 weeks according to the study protocol. Several parameters (i.e., MDS-UPDRS, CGI-C, K-NMSS, modified Hoehn-Yahr stage and SNBR) will be evaluated to assess the efficacy of vutiglabridin. Assessments including measurement of vital signs, 12-lead ECG, clinical laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed to evaluate the safety and tolerability of vutiglabridin. Blood samples will be collected for pharmacokinetic assessment., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Vutiglabridin, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change From Baseline in MDS-UPDRS Part III Subscore, secondaryOutcomes measure: Change From Baseline in MDS-UPDRS Part III Subscore, secondaryOutcomes measure: Change From Baseline in MDS-UPDRS Part II + Part III, secondaryOutcomes measure: Change From Baseline in CGI-C score, secondaryOutcomes measure: Change From Baseline in K-NMSS score, secondaryOutcomes measure: Change From Baseline in Modified Hoehn-Yahr stage, secondaryOutcomes measure: Change From Baseline in PET SNBR (Specific to Non-specific Binding Ratio) in the putamen, acudate and nucleus, secondaryOutcomes measure: Drop-out rate due to taking anti-parkinson drug, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False